BioSpace News Archive

Spero Therapeutics, Inc. today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeek TM 2021, taking place virtually from September 29 – October 3, 2021.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced its Phase 1b open-label dose-escalation clinical trial of camsirubicin in the US is active and recruiting patients

Scipher Medicine today announced a partnership with Ventegra, Inc., a new class-of-trade Medical Benefits Manager that uses innovative programs and products to ensure appropriate use of prescription drugs while lowering clients’ costs.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that the Company will present a trial in progress update on FS120, a first-in-class OX40 and CD137 tetravalent dual T cell agonist, at the European Society for Medical Oncology 2021 Conference,

NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that preliminary findings from its ongoing, open-label Phase 1a/1b dose escalation study of NGM120, a novel GFRAL antagonist antibody, in patients with advanced solid tumors are being presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021,

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the pricing of an underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00 per share.

The outbreak of COVID-19 has adversely impacted various industries across the world.

The increasing rate of investment for R & D activities to develop and promote the services will boost growth opportunities in the human combination vaccines market.

The expanding predominance of gynecological issues, like uterine irregularities, unusual uterine dying, uterine fibroids, and fruitfulness issues, is a key factor driving the market development.

Solutions from the global artificial intelligence in genomics market are widely used in precision medicine as well as drug discovery branches of the healthcare and pharmaceutical industries.